Paper - WANFANG MED ONLINE

You Position: Home > Paper

Novel combination approaches for myeloma:reports from the 57th American Society of Hematology annual meeting

( views:178, downloads:184 )

Author:: No author available

Journal Title:: 白血病·淋巴瘤

Issue:: 2

DOI:: 10.3760/cma.j.issn.1009-9921.2016.02.008

Key Word:: 多发性骨髓瘤;新药;治疗反应;美国血液学会年会;Multiple myeloma;New drugs;Response;American Society of Hematology annual meeting

Abstract： As understanding the biology of multiple myeloma (MM) and application of new drugs, regimens containing new drugs deepened therapeutic response and prolonged the survival of MM patients. This article updates the therapeutic response of regimens reported in the 57th American Society of Hematology annual meeting, containing immunomodulatory agents, proteasome inhibitors, histone deacetylase inhibitors and other new drugs including monoclonal antibodies and the others. In the same time, minimal residual disease (MRD) is also used to evaluate the remission depth of MM. In order to achieve durable long-term remission and higher quality of life, new drug combination regimens have been recommended, especially for the relapsed or the high risk MM patients.

Reference

[1]Stewart, A. Keith,Rajkumar, S. Vincent,Dimopoulos, Meletios A.,etc.Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma[J].2015,372(2).
[2]Palumbo A,Bringhen S,Rossi D,etc.Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.[J].2010,28(34).
[3]Iwai Y,Ishida M,Tanaka Y,etc.Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.[J].2002,99(19).
[4]Zheng, Zhaohui,Bagg, Adam,Mahnke, Yolanda D.,etc.Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma[J].2015,373(11).
[5]Wang,M.,Martin,T.,Bensinger,W.,etc.Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma[J].2013,122(18).
[6]Lonial, Sagar,Dimopoulos, Meletios,Palumbo, Antonio,etc.Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma[J].2015,373(7).
[7]Berdeja, Jesus G.,Hart, Lowell L.,Mace, Joseph R.,etc.Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma[J].2015,100(5).
[8]Sonneveld,P.,Schmidt-Wolf,I.G.H.,VanDerHolt,B.,etc.Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/GMMG-HD4 trial[J].2012,30(24).
[9]Sagar, Lonial,Ajay K, Nooka.Novel combination approaches for myeloma.[J].2015,2015(1).
[10]Dimopoulos MA,Deraedt W,Golenkov A,etc.Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.[J].2010,116(19).
[11]Richardson PG,Weller E,Lonial S,etc.Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.[J].2010,116(5).
[12]Wolf,J.,Mulligan,G.,Stewart,A.K.,etc.Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma[J].2012,119(19).
[13]Lafon,I.,Chaleteix,C.,Gahrton,G.,etc.Superiority of the triple combination of bortezomib-thalidomide- dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: The MMVAR/IFM 2005-04 random[J].2012,30(20).
[14]Benboubker,L.,Dimopoulos,M.A.,Dispenzieri,A.,etc.Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma[J].2014,371(10).
[15]Rawstron, Andy C.,Gregory, Walter M.,de Tute, Ruth M.,etc.Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction[J].2015,125(12).
[16]Sonneveld, Pieter,Asselbergs, Emilie,Zweegman, Sonja,etc.Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma[J].2015,125(3).
[17]Weber DM,Niesvizky R,Attal M,etc.Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.[J].2009,23(11).
[18]Zamagni E,Patriarca F,Nanni C,etc.Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.[J].2011,118(23).
[19]McCarthy,P.L.,Owzar,K.,Hofmeister,C.C.,etc.Lenalidomide after stem-cell transplantation for multiple myeloma[J].2012,366(19).
[20]Paul G Richardson,Wanling Xie,Sundar Jagannath,etc.A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.[J].2014,123(10).
[21]Dimopoulos,M.,Siegel,D.S.,Lonial,S.,etc.Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): A multicentre, randomised, double-blind study[J].2013,14(11).
[22]Prashant Kapoor,Shaji K. Kumar,Angela Dispenzieri,etc.Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma[J].2013,31(36).
[23]Attal,M.,Lauwers-Cances,V.,Marit,G.,etc.Lenalidomide maintenance after stem-cell transplantation for multiple myeloma[J].2012,366(19).
[24]Paul G Richardson,Robert L Schlossman,Melissa Alsina,etc.PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.[J].2013,122(14).